Premium
A double‐blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
Author(s) -
Chan Waichi,
Lam Linda Chiuwa,
Choy Caroline Ngapui,
Leung Vivian Puiyiu,
Li Siuwah,
Chiu Helen Fungkum
Publication year - 2001
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/gps.504
Subject(s) - risperidone , haloperidol , dementia , extrapyramidal symptoms , psychology , psychiatry , medicine , alzheimer's disease , schizophrenia (object oriented programming) , antipsychotic , disease , dopamine
Background Behavioural and psychological symptoms (BPSD) are common during the course of dementia and present severe problems to patients and their caregivers. Objectives To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients. Methods A 12‐week double‐blind randomised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM‐IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. Clinical response was evaluated using the Cohen‐Mansfield Agitation Inventory (CMAI), the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE‐AD), Simpson‐Angus Scale, Functional Assessment Staging and Cantonese version of the Mini‐Mental State Examination. Results The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of BPSD (scores on CMAI and BEHAVE‐AD), with no significant between‐group differences. Haloperidol‐treated patients showed a worsening on Simpson‐Angus scale while there was no significant change in this measure in risperidone‐treated patients. Conclusions Low‐dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia. Risperidone may have a more favourable risk‐benefit profile in view of its lower propensity to induce extrapyramidal symptoms. Copyright © 2001 John Wiley & Sons, Ltd.